Can Oral Ketorolac (Toradol) Be Prescribed for Migraines?
Yes, oral ketorolac can be prescribed for migraine treatment, but only as continuation therapy following initial IV or IM administration, and it is not a first-line option according to current guidelines.
Key Limitations and Prescribing Context
The FDA-approved indication for oral ketorolac is highly restrictive 1:
- Oral ketorolac should NOT be given as an initial dose for migraine treatment
- It is only indicated as continuation therapy after IV or IM ketorolac administration
- The combined duration of parenteral plus oral ketorolac must not exceed 5 days in adults
- Oral ketorolac is not approved for patients under 17 years of age
Guideline-Based Treatment Algorithm
According to the 2025 American College of Physicians guidelines 2, the recommended approach for acute episodic migraine is:
First-Line Treatment:
- Start with NSAIDs (such as ibuprofen, naproxen, aspirin) or acetaminophen at adequate doses
- Consider the combination of aspirin-acetaminophen-caffeine
Second-Line Treatment:
- If inadequate response to first-line NSAIDs, add a triptan to the NSAID (or to acetaminophen if NSAIDs contraindicated)
- This combination therapy should be initiated as soon as possible after migraine onset
Ketorolac's Role:
While ketorolac is an NSAID, the guidelines specifically mention other NSAIDs (aspirin, celecoxib, diclofenac, ibuprofen, naproxen) but do not highlight ketorolac as a preferred oral agent 2. The evidence base for ketorolac is primarily in parenteral formulations for emergency department settings 3.
Evidence for Ketorolac in Migraine
Parenteral ketorolac (IV/IM) has demonstrated efficacy:
- IV ketorolac is considered "likely effective" and should be offered in emergency department settings 3
- Meta-analyses show ketorolac has similar efficacy to phenothiazines and metoclopramide for acute migraine 4
- Intranasal ketorolac is non-inferior to IV ketorolac in children 5
However, oral ketorolac specifically lacks robust evidence as a standalone migraine treatment in the literature reviewed.
Practical Prescribing Guidelines
If prescribing oral ketorolac as continuation therapy 1:
For patients age 17-64 years:
- 20 mg PO once, then 10 mg every 4-6 hours as needed
- Maximum 40 mg/day
For patients ≥65 years, renally impaired, or <50 kg:
- 10 mg PO once, then 10 mg every 4-6 hours as needed
- Maximum 40 mg/day
Critical Safety Considerations
Cardiovascular risks 1:
- Increased risk of MI, stroke, and CV thrombotic events
- Contraindicated post-CABG surgery
- Avoid in patients with recent MI unless benefits outweigh risks
- Can worsen hypertension and heart failure
Gastrointestinal risks 6:
- Risk of serious GI bleeding increases markedly with high doses >5 days, especially in elderly
- The risk profile parallels other NSAIDs
Renal risks 1:
- Acute renal failure may occur (usually reversible)
- Use caution in renally impaired patients
Medication overuse headache 2:
- NSAIDs can cause medication overuse headache when used ≥15 days per month
- This threshold is higher than for triptans (≥10 days/month)
Bottom Line Recommendation
For oral migraine treatment, prescribe other NSAIDs (ibuprofen, naproxen) or the aspirin-acetaminophen-caffeine combination as first-line agents rather than oral ketorolac 2. These have better evidence, fewer restrictions, and can be used as initial therapy. Reserve oral ketorolac only for the specific FDA-approved indication: continuation therapy after parenteral ketorolac in the emergency department setting, with strict adherence to the 5-day maximum duration 1.
If a patient requires parenteral therapy in the ED, IV ketorolac is a reasonable option 3, but transition to standard oral NSAIDs or triptan-NSAID combinations for ongoing management rather than continuing oral ketorolac.